JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A2585 MG-132
26 Citation

Target: Proteasome

Summary: Proteasome inhibitor, Cell permeable, reversible

≥23.78 mg/mL
A4127 GSK1070916

Target: Aurora Kinases

Summary: Aurora B/C inhibitor

≥25.4 mg/mL
A2614 Bortezomib (PS-341)
24 Citation

Target: Proteasome

Summary: Proteasome Inhibitor

insoluble in EtOH; insoluble in H2O; ≥19.21 mg/mL
A3336 CVT-313
1 Citation

Target: Cyclin-Dependent Kinases

Summary: Cdk2 inhibitor

≥20 mg/mL
A8320 PF-00562271

Target: FAK|Pyk2

Summary: FAK/Pyk2 inhibitor,potent and ATP-competitive

insoluble in EtOH; insoluble in H2O; ≥11.1 mg/mL
A8336 KU-60019
2 Citation

Target: ATM/ATR

Summary: ATM kinase inhibitor,potent and selective

≥27.4 mg/mL
A8345 PF-562271 HCl

Target: FAK|Pyk2

Summary: FAK/Pyk2 inhibitor

≥26.35 mg/mL
A8440 GSK1838705A

Target: Insulin and Insulin-like Receptors|ALK

Summary: IGF-IR/IR/ALK inhibitor, ATP-competitive

≥26.65 mg/mL
A8441 GSK461364
3 Citation

Target: PLK

Summary: Plk1 inhibitor
B2176 GSK1059615

Target: PI3K|mTOR

Summary: PI3K and mTOR inhibitor,potent and reversible

insoluble in EtOH; insoluble in H2O; ≥8.33 mg/mL